Shareholders in Octopus Renewables Infrastructure Trust (LON:ORIT) are in the red if they invested three years ago
So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.
This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.
To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
During the three years that the share price fell, Octopus Renewables Infrastructure Trust's earnings per share (EPS) dropped by 36% each year. In comparison the 14% compound annual share price decline isn't as bad as the EPS drop-off. So the market may not be too worried about the EPS figure, at the moment -- or it may have previously priced some of the drop in.
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
This free interactive report on Octopus Renewables Infrastructure Trust's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, Octopus Renewables Infrastructure Trust's TSR for the last 3 years was -22%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!
It's good to see that Octopus Renewables Infrastructure Trust has rewarded shareholders with a total shareholder return of 14% in the last twelve months. And that does include the dividend. Notably the five-year annualised TSR loss of 1.3% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. It's always interesting to track share price performance over the longer term. But to understand Octopus Renewables Infrastructure Trust better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for Octopus Renewables Infrastructure Trust (of which 1 makes us a bit uncomfortable!) you should know about.
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on British exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Coface SA: Coface agrees to acquire Novertur International SA (business-monitor.ch), enhancing its Business Information offer in Switzerland
Coface agrees to acquire Novertur International SA ( enhancing its Business Information offer in Switzerland Paris, 17 July 2025 – 18.30 Coface announces the signing of an agreement to acquire 100% of Novertur International SA. Novertur International SA, a Swiss startup based in Lausanne, has developed strong digital expertise in managing data on Swiss companies, which it distributes through its platform Launched in 2016, the platform has become a key tool for SMEs and large companies in Switzerland for risk management and B2B prospecting. It offers simple, fast and reliable access to up-to-date information on more than 730,000 active Swiss businesses. The technological innovations developed by Novertur International SA - particularly in data structuring and user experience - combined with Coface's expertise in credit risk, will significantly strengthen Coface's Business Information offering in Switzerland. This acquisition strengthens the Group's data, technical capabilities and expertise, in full alignment with its strategic plan Power the Core, which aims to enhance its high value-added services while strengthening its local presence. Florent Schlaeppi, CEO and Founder of commented: 'From day one, we designed to be intuitive, fast, and useful for anyone analyzing companies. Joining Coface is a tremendous opportunity to take our mission to the next level by putting our technology at the service of a global player in business risk.' Christian Moins, Country Manager Coface Switzerland, commented: 'We are particularly excited to welcome the Business Monitor team to Coface. The acquisition of Business Monitor demonstrates Coface's ambition to establish itself as a key player in Business Information. This transaction significantly strengthens our position in the Swiss market, making Coface an even more attractive partner for its clients. ' The completion of the acquisition remains subject to the usual closing conditions. CONTACTS ANALYSTS / INVESTORSThomas JACQUET: +33 1 49 02 12 58 – Rina ANDRIAMIADANTSOA: +33 1 49 02 15 85 – MEDIA RELATIONSSaphia GAOUAOUI: +33 1 49 02 14 91 – BILLET: +33 1 49 02 23 63 – FINANCIAL CALENDAR 2025(subject to change)H1-2025 results: 31 July 2025 (after market close) 9M-2025 results: 3 November 2025 (after market close) FINANCIAL INFORMATIONThis press release, as well as COFACE SA's integral regulatory information, can be found on the Group's website: For regulated information on Alternative Performance Measures (APM), please refer to our Interim Financial Report for H1-2024 and our 2024 Universal Registration Document (see part 3.7 'Key financial performance indicators'). Regulated documents posted by COFACE SA have been secured and authenticated with the blockchain technology by can check the authenticity on the website COFACE: FOR TRADEAs a global leading player in trade credit risk management for more than 75 years, Coface helps companies grow and navigate in an uncertain and volatile environment. Whatever their size, location or sector, Coface provides 100,000 clients across some 200 markets with a full range of solutions: Trade Credit Insurance, Business Information, Debt Collection, Single Risk insurance, Surety Bonds, day, Coface leverages its unique expertise and cutting-edge technology to make trade happen, in both domestic and export markets. In 2024, Coface employed ~5,236 people and registered a turnover of €1.84 billion. COFACE SA is quoted in Compartment A of Euronext ParisCode ISIN: FR0010667147 / Ticker: COFA DISCLAIMER - Certain declarations featured in this press release may contain forecasts that notably relate to future events, trends, projects or targets. By nature, these forecasts include identified or unidentified risks and uncertainties, and may be affected by many factors likely to give rise to a significant discrepancy between the real results and those stated in these declarations. Please refer to chapter 5 'Main risk factors and their management within the Group' of the Coface Group's 2024 Universal Registration Document filed with AMF on 3 April 2025 under the number D.25-0227 in order to obtain a description of certain major factors, risks and uncertainties likely to influence the Coface Group's businesses. The Coface Group disclaims any intention or obligation to publish an update of these forecasts, or provide new information on future events or any other circumstance. Attachment 2025 07 17 PR Novertur acquisition agreementError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
OSE Immunotherapeutics Launches Newsletter for Individual Shareholders NANTES, France, July 17, 2025, 6:30pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs, today launched the inaugural edition of its Newsletter, designed specifically for individual shareholders and investors in France and internationally. " This year, OSE Immunotherapeutics celebrates the 10th anniversary of its listing on Euronext Paris and we are delighted to introduce this new communication channel for our valued individual shareholders" said Fiona Olivier, Chief Corporate Affairs & Investor Relations Officer of OSE Immunotherapeutics. " Beyond providing updates on Company developments, the Newsletter gives us an opportunity to shine a spotlight on our teams and offer deeper insights into topics that are typically only touched on in press releases. It's also a way for us to express our appreciation for the continued trust and support of our investor community. " Published regularly in French and English, the Newsletter will be available in the 'Investors' section of the OSE Immunotherapeutics website. To subscribe to receive our Newsletters: ABOUT OSE IMMUNOTHERAPEUTICSOSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Click and follow us on LinkedIn. Follow us on Fiona Dé France Contact Media: FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Contact Media:RooneyPartners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statements This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachment EN_250717_Newsletter_vfError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 minutes ago
- Yahoo
Report – Inter Milan Submit Official Bid To Atalanta For Nigeria Star
Inter Milan have submitted their first official bid to Atalanta for forward Ademola Lookman. This according to Italian broadcaster Sky Sport Italia, via FCInterNews. They report that the Nerazzurri are offering €40 million, whilst La Dea want €50 million. In the last couple days, a bombshell has emerged regarding Inter's summer transfer plans. Reportedly, the Nerazzurri have been in talks to sign Atalanta forward Ademola Lookman. Inter's interest in the 27-year-old is more than just a passing interest. They have already approached the player, who is keen to make the move. Sky Sport Italia confirm that Lookman has already agreed personal terms with Inter. He wants to make the move. Inter Make First Official Offer To Atalanta For Ademola Lookman Furthermore, Sky report that Inter have submitted an official offer to Atalanta for Ademola Lookman. The broadcaster report that the Nerazzurri have put a bid worth €40 million on the table. However, La Dea are still seeking more than that, according to Sky. They report that the Bergamo-based club are still demanding a fee of €50 million for Lookman. Therefore, the clubs will have to try and come together on a fee in negotiations. In this respect, add-ons or even the addition of a player going the other way could be key to resolving negotiations.